骨修饰剂在多发性骨髓瘤中的作用:美国临床肿瘤学会临床实践指南更新
美国临床肿瘤学会(ASCO)更新专家组通过针对性系统文献综述,纳入35项相关研究,更新了骨修饰剂在多发性骨髓瘤中的推荐。推荐对需要全身治疗的活动性症状性多发性骨髓瘤患者静脉给予帕米膦酸90 mg(至少2小时)或唑来膦酸4 mg(至少15分钟),每3至4周一次;地舒单抗在预防骨骼相关事件方面非劣于唑来膦酸,可作替代选择。
要点
- 活动性症状性多发性骨髓瘤需全身治疗者,推荐静脉帕米膦酸或唑来膦酸每3至4周一次。
- 地舒单抗预防骨骼相关事件非劣于唑来膦酸,肾毒性不良事件较少,可优先选用。
- 骨修饰治疗建议持续至多2年;疾病复发时应重新开始治疗。
核心结论
- 更新证据支持当前推荐,地舒单抗预防骨骼相关事件非劣于唑来膦酸且肾毒性不良事件较少。
研究设计与样本
- 更新专家组通过检索PubMed和Cochrane Library,针对随机对照试验、系统综述、Meta分析、临床实践指南和观察性研究进行针对性系统文献综述。
- 共识别35项相关研究。
主要发现
- 地舒单抗在预防骨骼相关事件方面非劣于唑来膦酸,并提供替代选择。
- 与唑来膦酸相比,地舒单抗的肾毒性相关不良事件较少,在此情况下可能优先选用。
- 唑来膦酸未在严重肾功能损害患者中研究,不推荐在此情况下使用。
关键数值与推荐
- 对需要全身治疗的活动性症状性多发性骨髓瘤患者,无论平片或其他影像学检查是否有溶骨性破坏或骨质疏松性脊柱压缩性骨折证据,推荐静脉给予帕米膦酸90 mg(至少2小时)或唑来膦酸4 mg(至少15分钟),每3至4周一次。
- 更新专家组推荐临床医生考虑对已有肾功能损害的患者降低帕米膦酸初始剂量。
- 更新专家组建议骨修饰治疗持续至多2年。
- 已评估较低频率给药,对缓解或稳定疾病患者应考虑采用。
- 持续使用由治疗医生根据持续骨骼疾病风险决定;疾病复发时应重新开始治疗。
临床怎么用
- 对需要全身治疗的活动性症状性多发性骨髓瘤患者,静脉给予帕米膦酸90 mg(至少2小时)或唑来膦酸4 mg(至少15分钟),每3至4周一次。
- 地舒单抗可作替代选择,肾毒性相关不良事件较少,可能优先选用。
- 对已有肾功能损害患者,考虑降低帕米膦酸初始剂量;唑来膦酸不推荐用于严重肾功能损害。
- 骨修饰治疗建议持续至多2年;对缓解或稳定疾病患者考虑较低频率给药;疾病复发时重新开始治疗。
- 持续使用由治疗医生根据持续骨骼疾病风险决定;更新专家组讨论了颌骨坏死的相关措施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To update guideline recommendations on the role of bone-modifying agents in multiple myeloma. Methods An update panel conducted a targeted systematic literature review by searching PubMed and the Cochrane Library for randomized controlled trials, systematic reviews, meta-analyses, clinical practice guidelines, and observational studies. Results Thirty-five relevant studies were identified, and updated evidence supports the current recommendations. Recommendations For patients with active symptomatic multiple myeloma that requires systemic therapy with or without evidence of lytic destruction of bone or compression fracture of the spine from osteopenia on plain radiograph(s) or other imaging studies, intravenous administration of pamidronate 90 mg over at least 2 hours or zoledronic acid 4 mg over at least 15 minutes every 3 to 4 weeks is recommended. Denosumab has shown to be noninferior to zoledronic acid for the prevention of skeletal-related events and provides an alternative. Fewer adverse events related to renal toxicity have been noted with denosumab compared with zoledronic acid and may be preferred in this setting. The update panel recommends that clinicians consider reducing the initial pamidronate dose in patients with preexisting renal impairment. Zoledronic acid has not been studied in patients with severe renal impairment and is not recommended in this setting. The update panel suggests that bone-modifying treatment continue for up to 2 years. Less frequent dosing has been evaluated and should be considered in patients with responsive or stable disease. Continuous use is at the discretion of the treating physician and the risk of ongoing skeletal morbidity. Retreatment should be initiated at the time of disease relapse. The update panel discusses measures regarding osteonecrosis of the jaw. Additional information is available at www.asco.org/hematologic-malignancies-guidelines and www.asco.org/guidelineswiki .
引用
- Anderson K, Ismaila N, Flynn PJ, et al. Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018. PMID: 29341831. doi:10.1200/JCO.2017.76.6402
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。